Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFD | P00746 | 17/20 | 0.49 |
| ▸ | TPSB2 | P20231 | 8/20 | 0.48 |
| ▸ | F11 | P03951 | 8/20 | 0.48 |
| ▸ | PLAU | P00749 | 2/20 | 0.48 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.48 |
| ▸ | PLG | P00747 | 1/20 | 0.48 |
| ▸ | F7 | P08709 | 1/20 | 0.48 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29852527 | 1.00 | CFD (0.49) | CFDTPSB2F11PLAUKLKB1 | |
| SCHEMBL23218523 | 0.91 | CFD (0.51) | CFDTPSB2F11PLAUKLKB1 | |
| SCHEMBL29852801 | 0.91 | CFD (0.51) | CFDTPSB2F11PLAUKLKB1 | |
| SCHEMBL29853125 | 0.91 | CFD (0.50) | CFDTPSB2F11PLAUKLKB1 | |
| SCHEMBL23219239 | 0.91 | CFD (0.50) | CFDTPSB2F11PLAUKLKB1 | |
| SCHEMBL23218360 | 0.89 | CFD (0.53) | CFDTPSB2F11PLAUKLKB1 | |
| SCHEMBL29852903 | 0.89 | CFD (0.53) | CFDTPSB2F11PLAUKLKB1 | |
| SCHEMBL23218758 | 0.89 | CFD (0.62) | CFDTPSB2F11PLAUKLKB1 | |
| SCHEMBL29852965 | 0.89 | CFD (0.62) | CFDTPSB2F11PLAUKLKB1 | |
| SCHEMBL23218479 | 0.89 | CFD (0.50) | CFDTPSB2F11PLAUKLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12558341-B2 | Oral complement factor D inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-20250186391-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2025-06-12 | — | — | US | disclosed |
| CN-114502168-A | Oral complement factor D inhibitors | 拜奥克里斯特制药公司 | 2022-05-13 | — | — | CN | disclosed |
| WO-2021072198-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2021-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12558341-B2 | Oral complement factor D inhibitors | CFD, CFH, CFB | CFD 1/4885TPSB2 419/4885F11 24/4885 |
| US-20250186391-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | CFD, CFH, CFB | CFD 1/4885TPSB2 498/4885F11 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.